Chest
Original ResearchPulmonary Vascular DiseaseOsteopontin in Patients With Idiopathic Pulmonary Hypertension
Section snippets
Patients and Study Design
The study was carried out in accordance with the Declaration of Helsinki and approved by the institutional review board (No. 3558). Written informed consent was obtained. This study consisted of the following two patient groups: a retrospective treatment-naive cohort (n = 70) and a prospective cohort (n = 25). Patients in the retrospective cohort were referred to Hannover Medical School (Hannover, Germany) between 2004 and 2008. The median surveillance time of the retrospective cohort was 24
OPN Levels in Patients With IPAH Are Elevated Compared With Control Subjects
Patient characteristics of the retrospective cohort are shown in Table 1. Baseline OPN levels in patients with pulmonary hypertension (n = 70, 50.2 ± 35.9 ng/mL) were significantly elevated compared with healthy control subjects (n = 40, 23.7 ± 2.8 ng/mL, P < .001) (Fig 1A). Healthy control subjects (n = 40) were matched for age (median, 52 years; IQR, 42–60 years) and sex (24 women, 16 men).
OPN and Clinical Characteristics at Baseline
In the retrospective cohort, baseline OPN levels correlated with age (r = 0.3, P = .02), 6-min walking
OPN and Outcome in IPAH
The present study showed that OPN plasma levels were significantly elevated in patients with IPAH compared with healthy control subjects. About two-thirds of the present study population presented with elevated OPN levels. These individuals had a poorer clinical status and an inferior prognosis compared with those with OPN levels below the upper reference limit. An OPN cutoff value of 34.5 ng/mL separated survivors from nonsurvivors with a sensitivity of 88% and a specificity of 63%. In
Acknowledgments
Author contributions: Dr Lorenzen: contributed the initial idea, performed the experiments, and wrote the manuscript.
Dr Nickel: contributed to the performance of the statistical analysis and wrote the manuscript.
Dr Krämer: contributed to the performance of the experiments.
Dr Golpon: contributed patient clinical data and to the performance of the statistical analysis.
Dr Westerkamp: contributed patient clinical data and to the performance of the statistical analysis.
Dr Olsson: contributed patient
References (44)
- et al.
Osteopontin: role in cell signaling and cancer progression
Trends Cell Biol
(2006) - et al.
JNK1 differentially regulates osteopontin-induced nuclear factor-inducing kinase/MEKK1-dependent activating protein-1-mediated promatrix metalloproteinase-9 activation
J Biol Chem
(2005) - et al.
Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IκBα kinase-dependent nuclear factor κB-mediated promatrix metalloproteinase-9 activation
J Biol Chem
(2004) - et al.
Distinct structural requirements for binding of the integrins αvβ6, αvβ3, αvβ5, α5β1 and α9β1 to osteopontin
Matrix Biol
(2005) - et al.
Analysis of the α4β1 integrin-osteopontin interaction
Exp Cell Res
(2000) - et al.
IL-1 up-regulates osteopontin expression in experimental crescentic glomerulonephritis in the rat
Am J Pathol
(1999) - et al.
TGFβ and BMP-2 activation of the OPN promoter: roles of smad- and hox-binding elements
Exp Cell Res
(2001) - et al.
Regulation of proximal tubular osteopontin in experimental hydronephrosis in the rat
Kidney Int
(1998) - et al.
Osteopontin may be responsible for pulmonary vascular remodeling
Chest
(2005) - et al.
Osteopontin: role in extracellular matrix deposition and myocardial remodeling post-MI
J Mol Cell Cardiol
(2010)
Endothelin-receptor antagonists in pulmonary hypertension
Lancet
NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension
Respir Med
Growth-differentiation factor-15 in heart failure
Heart Fail Clin
Clinical significance of brain natriuretic peptide in primary pulmonary hypertension
J Am Coll Cardiol
Osteopontin regulates renal apoptosis and interstitial fibrosis in neonatal chronic unilateral ureteral obstruction
Kidney Int
Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices
J Heart Lung Transplant
Primary pulmonary hypertension
N Engl J Med
Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation
Int J Exp Pathol
Osteopontin: a protein with diverse functions
FASEB J
Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene
Crit Rev Immunol
Angiotensinogen and AT(1) antisense inhibition of osteopontin translation in rat proximal tubular cells
Am J Physiol Renal Physiol
Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction
J Clin Invest
Cited by (77)
Increased Elastase and Matrix Metalloproteinase Levels in the Pulmonary Arteries of Infants With Congenital Diaphragmatic Hernia
2024, Journal of Pediatric SurgeryCell senescence in pulmonary hypertension
2022, Cellular Senescence in DiseasePost-translational regulation and proteolytic activity of the metalloproteinase ADAMTS8
2021, Journal of Biological ChemistryCerebrovascular damage after midlife transient hypertension in non-transgenic and Alzheimer's disease rats
2021, Brain ResearchCitation Excerpt :To gain a fuller understanding of the mechanisms underlying hypertensive remodeling in both NTg and TgAD rats, we isolated cortical blood vessels from all treatment groups and examined the expression of signaling proteins implicated in clinical and experimental hypertension. Osteopontin (OPN) is a secreted protein synthesized by smooth muscle and endothelial cells; modulation of OPN expression has been associated with hypertension as well as with post-insult vascular remodeling (Caesar et al., 2017; deBlois et al., 1996; Lorenzen et al., 2011). Here, we found that transient hypertension (p = 0.01) but not AD (p = 0.18) contributed to decreased OPN levels (Fig. 6A, B).
Biomarkers in Pulmonary Hypertension
2021, Encyclopedia of Respiratory Medicine, Second EditionCirculating NEDD9 is increased in pulmonary arterial hypertension: A multicenter, retrospective analysis
2020, Journal of Heart and Lung Transplantation
Drs Lorenzen and Nickel contributed equally to the study.
Funding/Support: This work was supported by the Deutsche Forschungsgemeinschaft [DFG LO 1736/1-1 to J. M. L. and SFB Transregio 37/project B4] and the European Commission under the 6th Framework Program [contract No. LSHM-CT-2005-018725, PULMOTENSION].
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).